Recent News

• 03.27.2025 - Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
• 03.27.2025 - Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
• 03.12.2025 - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
• 03.12.2025 - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
• 02.12.2025 - Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
• 02.12.2025 - Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
• 01.30.2025 - Portage Biotech Announces Completion of $2.15 Million Private Financing

Recent Filings

• 03.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.27.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.27.2025 - EX-99.1 EX-99.1
• 03.13.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.12.2025 - EX-99.1 EX-99.1
• 03.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.12.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 02.12.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 02.12.2025 - EX-99.1 EX-99.1